Skip to main content

Table 3 Multivariable Cox regression analyses for the relative risks of developing various IMIDs in AS patients when compared with non-AS individuals

From: Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study

IMID IMID occurred after the index date Excluding those with IMID within 3 months after the index date
HR (95% CI) P value HR (95% CI) P value
Acute anterior uveitis 9.07 (7.52–10.94)e < 0.01 10.98 (9.10–13.25)e < 0.01
Psoriasis 1.69 (1.24–2.29)f < 0.01 1.41 (1.01–1.96)e 0.04
Inflammatory bowel disease 2.11 (0.39–11.48)d 0.39 0.35 (0.06–2.06)e 0.24
Crohn’s disease 8.01 (1.79–35.79)c 0.01 2.74 (0.31–24.52)b 0.37
Ulcerative colitis 0.33 (0.05–2.37)f 0.27 0.33 (0.05–2.37)f 0.27
Systemic lupus erythematosus 0.93 (0.49–1.79)f 0.84 0.81 (0.40–1.64)f 0.56
Sjögren’s syndrome 2.05 (1.39–3.01)f < 0.01 1.29 (0.84–1.99)f 0.25
Rheumatoid arthritis 0.70 (0.50–0.99)f 0.04 0.46 (0.33–0.65)e < 0.01
Systemic sclerosis 1.65 (0.45–6.02)e 0.45 1.65 (0.45–6.02)e 0.45
Dermatomyositis 0.95 (0.22–4.02)f 0.94 0.29 (0.04–1.99)f 0.21
Polymyositis 7.96 (0.97–65.56)f 0.05 7.96 (0.97–65.56)f 0.05
Thromboangiitis obliterans 16.62 (2.78–99.52)a < 0.01 16.62 (2.78–99.52)a < 0.01
Behcet’s disease 20.37 (5.54–74.85)f < 0.01 26.20 (6.27–109.45)e < 0.01
Pemphigus 0.97 (0.07–13.48)d 0.98 0.97 (0.07–13.48)d 0.98
Sarcoidosis 5.39 (2.15–13.48)f < 0.01 6.09 (2.38–15.58)f < 0.01
Vitiligo 1.55 (0.73–3.32)f 0.26 1.42 (0.63–3.22)f 0.40
  1. Abbreviations: AS ankylosing spondylitis, IMID immune-mediated inflammatory disease, HR hazard ratio, CI confidence interval
  2. Adjusted variables: anone; bage; cage and sex; dage, sex and medications; eage, sex, medications and the frequency of visits; fage, sex, medications, the frequency of visits and Charlson comorbidity index. Models with the least Akaike information criterion were selected